{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vertigo/prescribing-information/cyclizine/","result":{"pageContext":{"chapter":{"id":"0d4b2274-af67-500e-a840-fcd41623b09e","slug":"cyclizine","fullItemName":"Cyclizine","depth":2,"htmlHeader":"<!-- begin field b3cde380-0751-42e4-8b54-a84800c50815 --><h2>Cyclizine</h2><!-- end field b3cde380-0751-42e4-8b54-a84800c50815 -->","summary":"","htmlStringContent":"<!-- begin item b8a7fb9a-8bd8-4ea4-a152-a84800c506b0 --><!-- end item b8a7fb9a-8bd8-4ea4-a152-a84800c506b0 -->","topic":{"id":"b94ca2c5-94f9-5b0b-8947-d7ed33aa5095","topicId":"d75cb8e1-a405-4add-9416-f4ddd4be71a4","topicName":"Vertigo","slug":"vertigo","lastRevised":"Last revised in November 2020","chapters":[{"id":"7cfbf245-8080-5408-b5af-46e6b015eaac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"eb7fafc8-c3da-5207-80f3-b71728b95977","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1a3b8a24-9e4d-5ef6-8305-9df3b1c317f2","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6c0480e-9ea3-560b-9ef9-010e2b6d6bc3","slug":"changes","fullItemName":"Changes"},{"id":"1d87a170-6a07-5578-be1a-88233309a577","slug":"update","fullItemName":"Update"}]},{"id":"3b505c43-ded3-5313-b4a7-fe0a2d033ba5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"53494a81-9a2a-5d95-bf7d-e77e711c0574","slug":"goals","fullItemName":"Goals"},{"id":"e1f01a8c-4094-553b-a76c-f2dd90a51b2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1cfd513c-3d5a-54aa-9602-3e6d3be38cba","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"25093d8c-33f4-5be7-9754-8089a9704300","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"969ceb1b-e8dd-5bee-8648-365304bee682","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"568bc797-4e2c-59a2-b4f8-b797d90d60b1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3f307c6b-3ea3-5ffd-8491-82b6cc0395f9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afc89990-521e-5fdd-ae17-ac351fe1d354","slug":"definition","fullItemName":"Definition"},{"id":"17376a5d-724c-5d04-a438-253fe0405224","slug":"causes","fullItemName":"Causes"},{"id":"d4691641-4de6-57f1-a02a-a9d5537caa0d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a5e55fa5-72d9-5ff4-923d-151c33d24a62","slug":"complications","fullItemName":"Complications"},{"id":"8264cee3-d774-5e04-a336-cbfe45355b60","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"375a4e7f-7fd0-5036-a3cc-6a0679c13bfa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ac52451f-5469-5c2c-8dee-9d89ff20b1fb","slug":"confirming-vertigo","fullItemName":"Confirming vertigo"},{"id":"c5647bfa-8ae2-597f-b367-8710ae469632","slug":"assessment","fullItemName":"Assessment"},{"id":"32b446b7-58ea-516a-9ba6-89e9bd5dfd13","slug":"determining-the-cause","fullItemName":"Determining the cause"}]},{"id":"47662437-22e1-5dc4-889b-55ff8cffa7c9","fullItemName":"Management","slug":"management","subChapters":[{"id":"c7179f67-2fd1-5f8f-8486-60029021ba78","slug":"central-vertigo","fullItemName":"Scenario: Central vertigo"},{"id":"fd3025fe-2a3b-5653-ae93-d9e6f65503c3","slug":"peripheral-vertigo","fullItemName":"Scenario: Peripheral vertigo"}]},{"id":"2947932c-9f33-58ca-8926-c2a8a66f953c","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"edb82728-4773-5ae4-81a1-a8069cbef357","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"0d4b2274-af67-500e-a840-fcd41623b09e","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"981f2355-58ab-5b91-b56a-649ae876203f","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"edf7a80f-dfc3-5b9c-a678-82dd7acddfbb","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"2b7a5cd7-2c2c-5be4-89b5-e3146e3c36e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3832ba17-fb19-511b-b3de-fc89bc2a3346","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bdd9780-7f08-58bd-bd56-e5043164ffdc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b8bb4197-e5b5-5db7-876b-584f0ac43071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d2c7a7b5-0d16-58aa-926f-96fa0fae0f86","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f217b9f5-f617-534d-bfb1-86ca071d3288","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"614e67fc-1003-5f73-90ed-fcc6fa8adc67","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a11a0d07-8592-5c4c-89c6-b318893454cd","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2947932c-9f33-58ca-8926-c2a8a66f953c","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9a20cea9-b897-5e1e-a3dd-54dcc6372b22","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field d79b1d4c-3db5-4c00-af71-a8480102cf0c --><h3>What dosage of cyclizine should I prescribe?</h3><!-- end field d79b1d4c-3db5-4c00-af71-a8480102cf0c -->","summary":"","htmlStringContent":"<!-- begin item 2b7fc82e-a502-47b8-8b4f-a8480102cc70 --><!-- begin field 83d7ad1e-b562-40a0-8565-a8480102cf0c --><ul><li>For nausea, vomiting, vertigo, or labyrinthine disorders, prescribe cyclizine 50 mg orally up to three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2015a</a>] <strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>]. </li><li>If the oral route is not appropriate, cyclizine 50 mg by intramuscular injection can be given up to three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>].</li></ul><!-- end field 83d7ad1e-b562-40a0-8565-a8480102cf0c --><!-- end item 2b7fc82e-a502-47b8-8b4f-a8480102cc70 -->","subChapters":[]},{"id":"b01011e9-c2cf-53b1-a8fb-d4db6689c7ae","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 976e00af-3d6c-40ac-9128-a8480102eea8 --><h3>What are the contraindications and cautions when prescribing cyclizine?</h3><!-- end field 976e00af-3d6c-40ac-9128-a8480102eea8 -->","summary":"","htmlStringContent":"<!-- begin item ea7ba1c8-f414-4c73-81d2-a8480102ec4a --><!-- begin field 171e9185-a740-4a90-a241-a8480102eea8 --><ul><li><strong>Do not prescribe cyclizine to people with:</strong><ul><li>Hypersensitivity to cyclizine or its excipients.</li><li>Severe liver disease — increased risk of coma.</li><li>Porphyria.</li></ul></li><li><strong>Prescribe cyclizine with caution to people with:</strong><ul><li>Prostatic hypertrophy, urinary retention, susceptibility to angle-closure glaucoma, and pyloroduodenal obstruction.</li><li>Hepatic disease.</li><li>Epilepsy.</li><li>Severe heart failure or acute myocardial infarction — cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure, and pulmonary wedge pressure.</li><li>Phaeochromocytoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2015a</a>] <strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>] </p><p> </p><!-- end field 171e9185-a740-4a90-a241-a8480102eea8 --><!-- end item ea7ba1c8-f414-4c73-81d2-a8480102ec4a -->","subChapters":[]},{"id":"f4cf0a72-3689-519a-99f6-78aae51a06ff","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ce2e7bfd-32ac-4fbd-8af1-a84801030e7e --><h3>What are the adverse effects of cyclizine?</h3><!-- end field ce2e7bfd-32ac-4fbd-8af1-a84801030e7e -->","summary":"","htmlStringContent":"<!-- begin item aa9ec53a-b1ca-44fc-be2c-a84801030d3b --><!-- begin field 084929de-1d80-4134-94e6-a84801030e7e --><ul><li><strong>Drowsiness</strong> is a significant adverse effect with most of the older antihistamines (such as cyclizine), especially with high doses or in the elderly.</li><li><strong>Other adverse effects include:</strong><ul><li>Psychiatric — restlessness, nervousness, euphoria, disorientation, insomnia, and auditory and visual hallucinations.</li><li>Neurological — headache, dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, seizures, dizziness, somnolence and decreased consciousness, speech disorders (transient), paraesthesia, and generalized chorea.</li><li>Cardiovascular — tachycardia, palpitations, arrhythmias, hypertension, and hypotension.</li><li>Respiratory — bronchospasm and apnoea.</li><li>Gastrointestinal and hepatic — dry mouth, nose and throat; constipation; increased gastric reflux; nausea, vomiting, and diarrhoea; stomach pain; loss of appetite; hepatic dysfunction; cholestatic jaundice and hepatitis.</li><li>Skin — rashes, urticaria, angio-oedema, allergic skin reactions, and fixed drug eruption photosensitivity.</li><li>Musculoskeletal — twitching and muscle spasms.</li><li>Immune system — hypersensitivity reactions, including anaphylaxis.</li><li>Blood and lymphatic system — agranulocytosis, haemolytic anaemia, leucopenia, and thrombocytopenia.</li><li>Others — tinnitus, blurred vision and oculogyric crisis, and urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2015a</a>] <strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>]</p><!-- end field 084929de-1d80-4134-94e6-a84801030e7e --><!-- end item aa9ec53a-b1ca-44fc-be2c-a84801030d3b -->","subChapters":[]},{"id":"daa2ab50-9abd-532b-ac13-065a19375a36","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8d0c0eed-4b30-4059-a4ae-a848010326a2 --><h3>What drug interactions occur with cyclizine?</h3><!-- end field 8d0c0eed-4b30-4059-a4ae-a848010326a2 -->","summary":"","htmlStringContent":"<!-- begin item d81b78fd-46e1-4bc8-9821-a84801032529 --><!-- begin field 5efc9cc5-cc4d-4026-9ddf-a848010326a2 --><ul><li>Important drug interactions with cyclizine include:<ul><li>Alcohol — the anti-emetic effect of cyclizine may increase the toxic effects of alcohol.</li><li>Antimuscarinic drugs — there is a risk of increased antimuscarinic adverse effects when cyclizine is given with other antimuscarinic drugs. </li><li>Central nervous system (CNS) depressant drugs — cyclizine may have additive effects with other CNS depressants, such as opioid analgesics.</li><li>Ototoxic drugs — cyclizine may disguise signs indicating the onset of damage caused by ototoxic drugs (such as aminoglycoside antibiotics).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2015a</a>] <strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>]</p><!-- end field 5efc9cc5-cc4d-4026-9ddf-a848010326a2 --><!-- end item d81b78fd-46e1-4bc8-9821-a84801032529 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}